(Benzoyl peroxide + clindamycin phosphate) is a Small Molecule owned by GSK, and is involved in 21 clinical trials, which were completed.

Benzoyl peroxide has anti-bacterial activity against propionibacterium acnes, the organism implicated in acne vulgaris. It has keratolytic activity and is sebostatic, counteracting the hyperkeratinisation and excessive sebum production associated with acne. Clindamycin penetrates bacteria cell wall resulting in inhibition of protein synthesis. It binds to the 50S ribosomal subunit (specifically to 23s RNA subunit) of susceptible microorganisms and inhibits the translocation of peptides thus interfering with bacterial protein synthesis. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes), an anaerobe found in sebaceous glands and follicles.

The revenue for (Benzoyl peroxide + clindamycin phosphate) is expected to reach a total of $352m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Benzoyl peroxide + clindamycin phosphate) NPV Report.

(Benzoyl peroxide + clindamycin phosphate) is currently owned by GSK.

(Benzoyl peroxide + clindamycin phosphate) Overview

Benzoyl peroxide and clindamycin phosphate (Duac/ Indoxyl) is a fixed dose combination which acts as anti-acne agent. It is formulated as gel for topical application. Duac is indicated for the topical treatment of mild to moderate acne vulgaris, particularly inflammatory lesions, in adults and adolescents aged 12 years and above.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – (Benzoyl peroxide + clindamycin phosphate)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Benzoyl peroxide + clindamycin phosphate)
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
Key Companies
  • Sponsor Company: GSK
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.